Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDL/Roche Targeting Broad Zenapax Asthma Label Under Development Deal

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Roche/Protein Design Labs will pursue a broad moderate to severe asthma indication for Zenapax (daclizumab) in an attempt to gain an advantage over Xolair, under a co-development agreement announced Sept. 16.

You may also be interested in...

PDL Focus Remains Nuvion, But 2007 Could Include Several Significant Deals

While PDL BioPharma hopes to advance its lead product Nuvion into a pivotal ulcerative colitis trial by mid-2007, the firm is also looking to expand its acute care portfolio through several anticipated partnerships and the acquisition of a commercial product.

Genentech/Novartis Xolair

Amendment to Genentech/Novartis' Xolair (omalizumab) BLA will be submitted by year-end, with an expected six-month review from FDA, Genentech tells analysts. The amendment will include data from the firms' 1,900-patient safety study, ALTO, bringing the total safety database to over 4,000 patients. FDA had deemed the size of the Xolair safety database inadequate and requested platelet monitoring safety data from ALTO, as well as data on subgroups and pharmacokinetics. The BLA, submitted in June 2000 for moderate to severe allergic asthma in adults and adolescents, received a "complete response" letter in July 200

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts